| Dr Dipakkumar Shantilal Patel, MD | |
|
11312 Old River Trl, Edmond, OK 73013-8338 | |
| (405) 796-7234 | |
| Not Available |
| Full Name | Dr Dipakkumar Shantilal Patel |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 49 Years |
| Location | 11312 Old River Trl, Edmond, Oklahoma |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164480687 | NPI | - | NPPES |
| 001261817 | Medicaid | CT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 24244 (Oklahoma) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Integris Baptist Medical Center, Inc | Oklahoma city, OK | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Anesthesia Medical Professionals Pllc | 5991970279 | 87 |
News Archive
Using advanced computer simulations, University of Utah College of Pharmacy researchers have produced moving images of a protein complex that is an important target for anti-cancer drugs.
At an industrial scale, compost, such as manure, is produced by mixing plant and animal waste. Manure, however, is likely to contain antibiotic-resistant genes if animals have been treated with antibiotics during their lifetime.
Patients with prostate cancer who receive high-dose radiation treatment and also take statin drugs commonly used to lower cholesterol have a 10 percent higher chance of being cured of their cancer at 10 years after diagnosis (76 percent), compared to those who don't take these medications (66 percent), according to a study presented at a scientific session October 31, 2007, at the American Society for Therapeutic Radiology and Oncology's 49th Annual Meeting in Los Angeles.
PHC, Inc., d/b/a Pioneer Behavioral Health, "Pioneer" or (the "Company"), a leading provider of inpatient and outpatient behavioral health services, reported financial results for the Company's 2010 second fiscal quarter ended December 31, 2009. The results exclude the operations of the Company`s research division, Pivotal Research Centers, Inc. ("Pivotal"), which was sold during the 2009 third fiscal quarter and was accounted for as a discontinued operation.
The immunotherapy drug pembrolizumab has demonstrated a favorable safety profile and "promising durable clinical activity" in pretreated patients who exhibit high levels of the PD-L1 protein in advanced stages of small cell lung cancer (SCLC) – an aggressive form of the disease
› Verified 8 days ago
| Entity Name | Oklahoma City Anesthesia, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629038450 PECOS PAC ID: 5597705335 Enrollment ID: O20050511000177 |
News Archive
Using advanced computer simulations, University of Utah College of Pharmacy researchers have produced moving images of a protein complex that is an important target for anti-cancer drugs.
At an industrial scale, compost, such as manure, is produced by mixing plant and animal waste. Manure, however, is likely to contain antibiotic-resistant genes if animals have been treated with antibiotics during their lifetime.
Patients with prostate cancer who receive high-dose radiation treatment and also take statin drugs commonly used to lower cholesterol have a 10 percent higher chance of being cured of their cancer at 10 years after diagnosis (76 percent), compared to those who don't take these medications (66 percent), according to a study presented at a scientific session October 31, 2007, at the American Society for Therapeutic Radiology and Oncology's 49th Annual Meeting in Los Angeles.
PHC, Inc., d/b/a Pioneer Behavioral Health, "Pioneer" or (the "Company"), a leading provider of inpatient and outpatient behavioral health services, reported financial results for the Company's 2010 second fiscal quarter ended December 31, 2009. The results exclude the operations of the Company`s research division, Pivotal Research Centers, Inc. ("Pivotal"), which was sold during the 2009 third fiscal quarter and was accounted for as a discontinued operation.
The immunotherapy drug pembrolizumab has demonstrated a favorable safety profile and "promising durable clinical activity" in pretreated patients who exhibit high levels of the PD-L1 protein in advanced stages of small cell lung cancer (SCLC) – an aggressive form of the disease
› Verified 8 days ago
| Entity Name | Anesthesia Medical Professionals Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1962785931 PECOS PAC ID: 5991970279 Enrollment ID: O20111215000187 |
News Archive
Using advanced computer simulations, University of Utah College of Pharmacy researchers have produced moving images of a protein complex that is an important target for anti-cancer drugs.
At an industrial scale, compost, such as manure, is produced by mixing plant and animal waste. Manure, however, is likely to contain antibiotic-resistant genes if animals have been treated with antibiotics during their lifetime.
Patients with prostate cancer who receive high-dose radiation treatment and also take statin drugs commonly used to lower cholesterol have a 10 percent higher chance of being cured of their cancer at 10 years after diagnosis (76 percent), compared to those who don't take these medications (66 percent), according to a study presented at a scientific session October 31, 2007, at the American Society for Therapeutic Radiology and Oncology's 49th Annual Meeting in Los Angeles.
PHC, Inc., d/b/a Pioneer Behavioral Health, "Pioneer" or (the "Company"), a leading provider of inpatient and outpatient behavioral health services, reported financial results for the Company's 2010 second fiscal quarter ended December 31, 2009. The results exclude the operations of the Company`s research division, Pivotal Research Centers, Inc. ("Pivotal"), which was sold during the 2009 third fiscal quarter and was accounted for as a discontinued operation.
The immunotherapy drug pembrolizumab has demonstrated a favorable safety profile and "promising durable clinical activity" in pretreated patients who exhibit high levels of the PD-L1 protein in advanced stages of small cell lung cancer (SCLC) – an aggressive form of the disease
› Verified 8 days ago
| Entity Name | Deaconess Anesthesia Services, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912432048 PECOS PAC ID: 0042587842 Enrollment ID: O20170526001532 |
News Archive
Using advanced computer simulations, University of Utah College of Pharmacy researchers have produced moving images of a protein complex that is an important target for anti-cancer drugs.
At an industrial scale, compost, such as manure, is produced by mixing plant and animal waste. Manure, however, is likely to contain antibiotic-resistant genes if animals have been treated with antibiotics during their lifetime.
Patients with prostate cancer who receive high-dose radiation treatment and also take statin drugs commonly used to lower cholesterol have a 10 percent higher chance of being cured of their cancer at 10 years after diagnosis (76 percent), compared to those who don't take these medications (66 percent), according to a study presented at a scientific session October 31, 2007, at the American Society for Therapeutic Radiology and Oncology's 49th Annual Meeting in Los Angeles.
PHC, Inc., d/b/a Pioneer Behavioral Health, "Pioneer" or (the "Company"), a leading provider of inpatient and outpatient behavioral health services, reported financial results for the Company's 2010 second fiscal quarter ended December 31, 2009. The results exclude the operations of the Company`s research division, Pivotal Research Centers, Inc. ("Pivotal"), which was sold during the 2009 third fiscal quarter and was accounted for as a discontinued operation.
The immunotherapy drug pembrolizumab has demonstrated a favorable safety profile and "promising durable clinical activity" in pretreated patients who exhibit high levels of the PD-L1 protein in advanced stages of small cell lung cancer (SCLC) – an aggressive form of the disease
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Dipakkumar Shantilal Patel, MD 11312 Old River Trl, Edmond, OK 73013-8338 Ph: (405) 796-7234 | Dr Dipakkumar Shantilal Patel, MD 11312 Old River Trl, Edmond, OK 73013-8338 Ph: (405) 796-7234 |
News Archive
Using advanced computer simulations, University of Utah College of Pharmacy researchers have produced moving images of a protein complex that is an important target for anti-cancer drugs.
At an industrial scale, compost, such as manure, is produced by mixing plant and animal waste. Manure, however, is likely to contain antibiotic-resistant genes if animals have been treated with antibiotics during their lifetime.
Patients with prostate cancer who receive high-dose radiation treatment and also take statin drugs commonly used to lower cholesterol have a 10 percent higher chance of being cured of their cancer at 10 years after diagnosis (76 percent), compared to those who don't take these medications (66 percent), according to a study presented at a scientific session October 31, 2007, at the American Society for Therapeutic Radiology and Oncology's 49th Annual Meeting in Los Angeles.
PHC, Inc., d/b/a Pioneer Behavioral Health, "Pioneer" or (the "Company"), a leading provider of inpatient and outpatient behavioral health services, reported financial results for the Company's 2010 second fiscal quarter ended December 31, 2009. The results exclude the operations of the Company`s research division, Pivotal Research Centers, Inc. ("Pivotal"), which was sold during the 2009 third fiscal quarter and was accounted for as a discontinued operation.
The immunotherapy drug pembrolizumab has demonstrated a favorable safety profile and "promising durable clinical activity" in pretreated patients who exhibit high levels of the PD-L1 protein in advanced stages of small cell lung cancer (SCLC) – an aggressive form of the disease
› Verified 8 days ago
Dr. Lloyd Robert Chance, D.O. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1800 Renaissance Blvd, Edmond, OK 73013 Phone: 405-359-2400 | |
Jeffrey Newton Pearce, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 110 N Midwest Blvd, Edmond, OK 73034 Phone: 405-209-8293 | |
Dr. Michael Alan Dehuff, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 1 S Bryant Ave, Edmond, OK 73034 Phone: 918-664-9892 Fax: 918-392-2945 | |
Dr. Charles C Weddle Jr., M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1800 Renaissance Blvd, Edmond, OK 73013 Phone: 405-359-2400 | |
Eric J Neller, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1800 Renaissance Blvd, Edmond, OK 73013 Phone: 405-359-2400 | |
Dr. Thomas Covington Pratt, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1 S Bryant Ave, Edmond, OK 73034 Phone: 918-664-9892 Fax: 918-664-2521 |